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KESAN PENGHALANG SALURAN KALSIUM DAN AGEN 
ANTIHIPERTENSI LAIN TERHADAP SIMPTOM TREK URINARI BAWAH 




Simptom trek urinari bahagian bawah (LUTS) merangkumi semua gejala 
urologi yang berkaitan dengan pembuangan air kecil, penyimpanan dan post-
mikturasi, yang dikaitkan dengan gangguan emosi yang hebat kepada pesakit dan 
beban ekonomi yang tinggi kepada masyarakat. Penghasilan LUTS adalah berkaitan 
dengan ubat-ubatan dan penyakit tertentu. Penghalang saluran kalsium (CCB) 
dipercayai terlibat dalam penghasilan atau keterukkan LUTS, namun maklumat 
mengenai korelasi itu jarang ditemui. Oleh itu, kajian ini direka untuk meneliti kesan 
CCBs pada LUTS dan kesannya terhadap corak tidur, kemurungan dan kualiti hidup 
pesakit (QOL). Kajian ini dijalankan dalam 2 fasa; Fasa-I termasuk kajian pengesahan 
psikometrik di mana Skor dalam bahasa Urdu tentang simptom prostate di peringkat 
antarabangsa (IPSS-Urdu) dibangun dan divalidasikan manakala Fasa-II adalah kajian 
rentas keratan untuk menilai kesan CCB mono- dan terapi gabungan pada LUTS. 
IPSS-Urdu dibangunkan melalui terjemahan dua langkah ke depan dan belakang, dan 
dinilai untuk sifat psikometriknya dalam kajian prospektif yang melibatkan pesakit (n 
= 267) yang menderita LUTS, yang dijalankan di Jabatan Urologi Pesakit Luar, 
Hospital Mayo, Lahore, Pakistan. Kebolehpercayaan keseluruhan IPSS-Urdu adalah 
memuaskan [Cronbach's alpha = 0.72, Koefisien Korelasi Intra Kelas (ICC) of 
simptom-soalan = 0.92 dan ICC QOL-indeks = 0.75]. Analisis faktor eksplorasi 
menunjukkan bahawa dua faktor adalah konsisten, yang bersama-sama menjelaskan 
59.8% varians. Analisis faktor konfirmator seterusnya menunjukkan model dua 




atas menunjukkan kebolehpercayaan, konvergen, dan kebolehulangan yang baik dan 
keberhasilan IPSS-Urdu. Fasa-II, kajian rentas keratan, dijalankan di 2 farmasi 
masyarakat dan satu hospital (Institut Kardiologi Punjab) di Lahore, Pakistan. Versi 
Bahasa Urdu IPSS, Jenkins Sleep Evaluation Questionnaire, Pusat Pengajian 
Epidemiologi Kajian Skala Kemurungan Pendek dan EQ-5D-3L digunakan untuk 
menilai LUTS, gangguan tidur, kemurungan dan QOL. Kelaziman keseluruhan LUTS 
adalah 74.9% (ringan 25.1%, sederhana 49% dan LUTS teruk 25.9%). Tidak terdapat 
perbezaan yang signifikan dalam skor IPSS antara dihydropyridine dan pengguna 
bukan-dihydropyridine (54.50 vs 48.88, p = 0.402). Skor IPSS adalah jauh lebih 
rendah dalam kalangan pengguna monoterapi CCB daripada pesakit yang mengambil 
CCB dengan penghalang beta (79.81 vs 106.54, p = 0.001), serta CCB dengan 
penghalang beta dan diuretik (62.25 vs 94.12, p < 0.001). Sekitar 33% pesakit 
dilaporkan mengalami masalah tidur yang kerap. Selepas penyesuaian pelbagai, 
polifarmasi, skor CESD dan LUTS didapati mempunyai perkaitan kemungkinan 
gangguan tidur yang lebih tinggi. Kelaziman kemurungan dalam kalangan peserta 
kajian adalah 67.6% dan LUTS, gangguan tidur dan penyakit kardiovaskular adalah 
peramal positif yang signifikan. Selain itu, pesakit dengan LUTS penting secara 
klinikal melaporkan kualiti hidup yang jauh lebih teruk dalam semua dimensi EQ-5D-
3L jika dibandingtan dengan mereka yang mengalami LUTS yang ringan. Sebagai 
kesimpulan, penemuan kajian semasa memperkukuhkan hubungkait CCB dan agen 
antihipertensi lain dengan gejala kencing dan kesannya mampu menyebabkan impak 






EFFECT OF CALCIUM CHANNEL BLOCKER WITH OTHER 
ANTIHYPERTENSIVE AGENTS ON LOWER URINARY TRACT 




Lower urinary tract symptoms (LUTS) include all urological symptoms 
related to voiding, storage and post-micturition, which are associated with great 
emotional distress to sufferers and high economic burden to the society. The 
development of LUTS is deemed to be associated with certain medications and 
diseases. Among the former, calcium channel blockers (CCBs) are believed to be 
involved in development or worsening of LUTS, however, information concerning 
such correlation is sparse. Therefore, the present study was designed to investigate the 
effects of CCBs on LUTS and its impact on patients‘ sleep pattern, depression and 
quality of life (QOL). This study was carried out in 2 phases; Phase-I included a 
psychometric validation study wherein the International Prostate Symptom Score-
Urdu (IPSS-Urdu) was developed and validated, whereas Phase-II was a cross-
sectional study to evaluate the effect of CCB mono- and combined-therapy on LUTS. 
IPSS-Urdu was developed by a two-step forward and back translation, and evaluated 
for its psychometric properties in a prospective study involving patients (n = 267) 
suffering from LUTS, conducted at the Outpatient Urology Department, Mayo 
Hospital, Lahore, Pakistan. Overall reliability of IPSS-Urdu was satisfactory 
[Cronbach‘s alpha = 0.72, Intra-Class Correlation Coefficient (ICC) of symptom-
questions = 0.92 and ICC of QOL index = 0.75]. Exploratory factor analysis revealed 
that two factors were consistent, which together explained 59.8% of the variance. 
Confirmatory factor analysis further showed two-factor model, with acceptable fitting 




constructive validity and reproducibility of the IPSS-Urdu. Phase-II, a cross-sectional 
study, was conducted at 2 community pharmacies and one hospital (Punjab Institute 
of Cardiology) at Lahore, Pakistan. Urdu versions of IPSS, Jenkins Sleep Evaluation 
Questionnaire, Center for Epidemiologic Studies Short Depression Scale and EQ-5D-
3L were used to assess LUTS, sleep disturbances, depression and QOL, respectively. 
Overall prevalence of LUTS was 74.9% (mild 25.1%, moderate 49.0% and severe 
LUTS 25.9%). There was no significant difference in IPSS score between 
dihydropyridine and non-dihydropyridine-users (p = 0.402) IPSS score was 
significantly lower among CCB monotherapy users than patients on CCB plus beta-
blockers (79.81 vs 106.54, p = 0.001) and CCB plus beta-blockers and diuretics 
(62.25 vs 94.12, p < 0.001). Around 33% patients reported having frequent sleep 
problems. After multivariable adjustment, polypharmacy, CESD score ≥ 10 and 
LUTS were found to be associated with higher odds of sleeping disturbances. The 
prevalence of depression among study participants was 67.6% and LUTS, sleep 
disturbances and cardiovascular disease were its significant positive predictors. 
Moreover, patients with clinically significant LUTS reported significantly worse 
quality of life in all dimensions of EQ-5D-3L as compared to those with mild LUTS. 
In conclusion, findings of the current study further strengthen the association of CCB 
and other antihypertensive agents with urinary symptoms and its deleterious impact 







1.1 Urinary tract 
Urinary tract is comprised of two components, upper and lower urinary tract, that are 
mutually dependent. Upper urinary tract includes kidneys and ureter while bladder 
and urethra are parts of lower urinary tract. This provides an intricate system of 
conduits that converts perpetual involuntary urine production by the kidneys into the 
voluntarily controlled elimination of urine under the right circumstances [1]. 
 
1.2 Lower urinary tract 
1.2.1 Bladder 
It is a hollow muscle-organ that plays key role in collection and storage of urine, and 
voiding at a right time and in a right place [1, 2]. It is tetrahedral when unfilled and 
oval-shaped after filling. The bladder apex is attached to the abdominal wall by 
urachus [3]. It consists of two main parts; the bladder body, situated above the two 
ureteric orifices, and the base, consisting bladder wall, trigone, deep detrusor and 
urethrovesicular junction [2]. Histologically, the bladder is formed of three layers; an 
adventitia (connective tissue layer), a middle smooth muscle layer known as detrusor 
urinae muscle, and urothelium (innermost layer) that provides an elastic barrier 
impervious to urine [1]. Detrusor urinae muscle is under the control of autonomic 
nervous system. Detrusor muscle is abundantly innervated with the following nerves 
[1]: 
 Predominant population consisting cholinergic nerves (parasympathetic) that 




 Sympathetic innervation which is present in high concentration towards the 
base and are very important in controlling the vasculature 
 Third population is non-adrenergic-non-cholinergic sensorimotor nerves and 
their role in controlling urinary bladder is unclear  
 
1.2.2 Urethra 
It is a fibromuscular tube that spans from bladder to the urinary meatus. It is 13-20 cm 
long in males and is divided into three parts [3]: 
 Prostatic urethra  
 Membranous urethra 
 Spongy or penile urethra 
In females, it is 3.8-5.1 cm long and is extended from the bladder neck to the external 
urethral orifice [3]. 
 
1.2.3 Urination process 
The urination cycle involves two different phases: storage phase and voiding phase 
[4]. During storage phase, the distensible properties of the urinary bladder let it 
increase its volume with slight alteration in intravesical pressures. Moreover, there is 
an inhibition of bladder contractions and increased resistance of bladder outlet due to 
the activation of smooth muscles by spinal sympathetic reflexes [5]. Resistance of 
bladder neck also increases due to an increased activity of external urethral-sphincter 





When the bladder is filled with urine, afferent signals from increased volume, tension, 
and nociceptive receptors are sent via pudendal and pelvic nerves to the sacral spinal 
cord [5]. From the spinal cord, these signals travel to the pontine micturition center. 
After processing these signals, voiding reflex is initiated from the brain. The efferent 
activity that follows produce craniosacral outflow and inhibit both sympathetic and 
somatic pathways. Consequently, the external urethral-sphincter relaxes and a 
synchronized bladder contraction causes disposal of urine [5, 7]. 
 
1.3 Lower urinary tract symptoms (LUTS)  
1.3.1 LUTS terminology 
Historically, a number of pseudo-diagnostic terms were used to describe urinary 
symptoms in men namely ―prostatism‖, ―symptoms of benign prostatic hyperplasia‖, 
and ―clinical benign prostatic hyperplasia‖. In early nineties, Paul Abrams coined the 
term ―lower urinary tract symptoms‖ (LUTS) to label patient complaints without 
implying their cause [8]. 
 
1.3.2 Classification of LUTS 
As per the International continence Society guidelines shown in Table 1.1, LUTS are 
divided into three categories of symptoms: voiding, storage and post-micturition 
symptoms [9]. Firstly, voiding symptoms are experienced during voiding phase of 
bladder and include weak stream, splitting or spraying, intermittent stream, hesitancy, 
straining and terminal dribble. Secondly, storage symptoms are experienced during 
filling phase and include increased daytime frequency, nocturia, urinary urgency and 




micturition and include post-voiding dribble and sensation of incomplete bladder 
emptying. This corroborates well with an earlier classification suggested by Wein [4, 
10] who suggested that urinary disorders would be more elegantly characterized as 
―failure to store‖ or ―failure to empty.‖ These urinary symptoms are progressive, age-





Table 1.1: Classification of lower urinary tract symptoms as recommended by the International Continence Society 
 
Classification Individual symptoms Description 
Storage 
symptoms 
Increased daytime frequency It is the complaint by the patient who considers that he/she voids too often by day 
Urgency It is the complaint of a sudden strong desire to pass urine which is difficult to defer 
Nocturia It is the complaint that the individual has to wake at night one or more times to 
void 
Urinary incontinence It is the complaint of any involuntary leakage of urine 
Stress urinary incontinence It is the complaint of involuntary urination on effort or exertion, or on sneezing or 
coughing 
Urge urinary incontinence It is the complaint of involuntary leakage of urine accompanied by or immediately 
preceded by urgency. It can present in various symptomatic forms; such as frequent 
small losses between micturitions or as a terrible leak with complete bladder 
emptying 
Mixed urinary incontinence It is the complaint of involuntary loss of urine associated with urgency and also 
with exertion, effort, sneezing or coughing 
Enuresis Any involuntary loss/leakage of urine. However, if patient complains loss of urine 
occurring during sleep then it should be labeled as nocturnal enuresis 
Continuous urinary incontinence It is the complaint of continuous leakage of urine 
Other types of urinary incontinence Urinary incontinence that may be situational e.g. incontinence during sexual 
intercourse or giggle incontinence 
Bladder sensation It is defined by five categories; 
Normal: individual is fully aware of bladder filling and increasing sensation up to 
a strong desire to void 
Increased: individual feels an early and persistent need to void 
Decreased: individual is aware of bladder filling but does not feel the need to void 
Absent: individual reports no feeling of bladder filling or desire to void 
Non-specific: individual reports no specific bladder sensation but may recognize 




Table 1.1: Continued... 
 
Classification Individual symptoms Description 
Voiding 
symptoms 
Weak stream It is described by the individual as his/her perception of decreased urine flow, 
generally compared to previous performance or in contrast to other individuals. 
Splitting or spraying It is described by the individual as urine splitting into two or more streams or 
spraying of urinary stream 
Intermittency It is described by the individual as urine flow which stops and starts, on one or 
more occasions, during urination 
Hesitancy It is described by the individual as difficulty starting micturition resulting in a 
delay in the onset of voiding after the 
individual is ready to urinate 
Straining It is described by the individual as muscular effort exerted to start, maintain or 
improve the urinary stream. 
Terminal dribbling It is described by the individual as prolonged last part of urination, when the flow 
has slowed to a trickle/dribble 
Post micturition 
symptoms 
Sensation of incomplete emptying It is a self-explanatory term for a sensation experienced by the individual after 
passing urine 
Post micturition dribbling It is described by the individual as an involuntary loss of urine immediately after 
he/she has finished passing urine, commonly after leaving the toilet in 
males, or after rising from the toilet in females 




1.4 Epidemiology of LUTS 
The prevalence rates of LUTS in different regions of the world are presented in Table 
1.2. Majority of the studies were conducted among men aged 40 years or older and 
either used the International Prostate Symptom Score (IPSS) or American Urological 
Association-Symptom Index (AUA-SI) to estimate the prevalence of LUTS. The 
overall prevalence of LUTS ranges from 19.4 to 30% in North and South America 
[12-16]. Guess et al. compared the prevalence of LUTS between Minnesota and 
Scottish men and found out that Minnesota men had higher symptom frequency and 
symptom bother scores [14]. Moreover, individuals at both study locations reported 
dribbling as the most common and bothersome symptom followed by the urgency to 
urinate.  
 
Estimated overall prevalence of LUTS in European nations ranges between 14-30% 
[17-24] whereas it has been reported to be 25-30% in Turkey [25-27]. In Asian 
countries, the lowest (6.3%) prevalence was reported in Malaysians [28]. Chapple et 
al. reported that 61% of their study participants fulfilled the criteria for LUTS in their 
study (South Korea: 68.2, China: 59.0 and Taiwan: 58.5%) [29]. Multi-national study 
of Boyle et al. revealed that 16.2 and 19.9% of Korean men and women had LUTS 
[17]. Moreover, they also showed that the prevalence of LUTS did not differ much in 
European and Asian individuals. Data from the New Zealand and Australia also 











Table 1.2: Epidemiology of lower urinary tract symptoms around the globe 
Author (s) [Ref.] Country Study design Study population Research 
instrument (s) 
Prevalence of LUTS 
Meigs et al. [12] USA Population-based 
Cohort study 
N = 1019 men, age 
40-70 years 
Self-designed 
questions to assess 
clinical BPH 
Prevalence of clinical 
BPH was 19.4%. 
Joseph et al. [13] USA Population-based 
study 
N = 708 African-
American men, age 
40-79 years 
AUA-SI Overall = 29.7% 
(moderate: 25.9% and 
severe: 3.8%) 






N = 2119 Minnesota 
men and 1385 Scottish 
men, age 40-79 years 
Self-designed 
questionnaire 
identical to AUA-SI 
Overall = NR, Men at 
both study sites reported 
dribbling as the most 
common and bother 
symptoms followed by 
urgency 




questions similar to 
AUA-SI 
Overall = 23% 
Moreira Jr et al. [16] Brazil Cross-sectional, 
population-based 
survey 
N = 3000 (M: 1500, F: 
1500), age ≥ 30 years 
Self-designed 
questionnaire 
including items from 
IPSS, OAB-V8, 
PPBC 
Overall = NR, 
Prevalence of any LUTS 
was 81.5 and 84.1 % in 
male and females, 
respectively 
AUA-SI = American Urological Association Symptom Index; BPH = Benign prostatic hyperplasia; IPSS = International prostate symptom 
score; LUTS = Lower urinary tract symptoms; NR = Not reported; OAB-V8 = 8-item overactive bladder questionnaire; PPBC = Patient 





Table 1.2: Continued... 
 
Author (s) [Ref.] Country Study design Study population Research 
instrument (s) 
Prevalence of LUTS 
Boyle et al. [17] The Netherlands, 
France, UK, 
Republic of Korea 
Population-based, 
cross-sectional survey 
N = 8769 (M:4979, 
F:3790), age 40-79 
years 
IPSS Overall LUTS in males 
and females, respectively 
Netherlands = 
20.7 and 18% 
France = 19.2 and 12.6% 
UK = 25.1 and 23.7% 
Republic of Korea = 16.2 
and 19.9% 
Bosch et al. [18] The Netherlands Community-based, 
randomized pilot study 
N = 502 men, age 55-
74 years 
IPSS Overall = 30% 
(moderate: 24% and 
severe 6%) 
Andersson et al. [19] Sweden Population-based 
prospective cohort 
study 
N = 40,000 men, age 
40-79 years 
IPSS Overall = 23% 
Seim et al. [20] Norway Population-based 
study 
N = 21964 men, age ≥ 
20 years 
IPSS Overall = 15.8% 
(moderate: 13.2% and 
severe: 2.6%) 
Haidinger et al. [21] Austria Population-based 
cross-sectional study 
N = 2400 men, age 
15-89 years 
IPSS Overall = 16.9% 
Norby et al. [22] Denmark Population-based 
study 
N = 5379 (M:4952 
and F:427) 
IPSS Overall = 28% for males 
and 20% for females 
Rohrman et al. [23] Switzerland Cohort study N = 8627 men, age  
35-75 years 
IPSS Overall = 24.7% 
(moderate: 22% and 
severe: 2.7%) 




Table 1.2: Continued... 
 
Author (s) [Ref.] Country Study design Study population Research 
instrument (s) 
Prevalence of LUTS 
Sagnier et al. [24] France Community-based 
nationwide study 
N = 2011 men, age 
50-80 years 
AUA-SI Overall = 14.2% 
(moderate: 13% and 
severe: 1.2%) 
Zumrutbas et al. [25] Turkey Cross-sectional 
population-based 
survey 
N = 1555 (M:636 and 
F:919), age ≥ 18 years 
Self-designed 
questionnaire using 
ICS definition to 
assess LUTS 
Overall =NR, 
Prevalence of voiding, 
storage and post-viding 
symptoms were 39.3, 
56.1 and 30.7%, 
respectively. 
Aki et al. [26] Turkey Cross-sectional study N = 266 men, age ≥ 40 
years 
IPSS Overall = 24.9% 
(moderate: 21.4% and 
severe: 3.5%) 
Ulock et al. [27] Turkey Population-based 
cross-sectional study 
N = 754 men, age ≥ 40 
years 
IPSS Overall = 30% 
(moderate: 24% and 
severe: 10%) 
Mariappan et al. [28] Malaysia Cross-sectional 
population-based 
survey 
N = 353 men, age ≥ 40 
years 
AUA-SI and IIEF Overall = 6.3% 
(moderate: 6.0% and 
severe: 0.3%) 





N = 8284 (M: F: ), age 
≥ 40 years 
IPSS and other ICS 
symptom questions 
Overall = 61% (South 
Korea: 68.2, China: 59.0 
and Taiwan: 58.5%) 
AUA-SI = American Urological Association Symptom Index; ICS = International continence Society; IIEF = International index of erectile 






Table 1.2: Continued... 
 
Author (s) [Ref.] Country Study design Study population Research 
instrument (s) 
Prevalence of LUTS 
Tsukamoto et al. 
[30] 
Japan NR N = 289 men, age 40-
79 years 
Questionnaire 
worded similarly to 
IPSS 
Overall = NR, the 
frequency of individuals 
in IPSS categories (mild, 
moderate and severe) 
increased significantly 
with age. 
Pinnock et al. [31] Australia Interview-based 
prevalence survey 
N = 2890 (M: 1204 
and F: 1686), age ≥ 18 
years 
IPSS Overall =NR, Prevalence 
of ≥ 1 troublesome LUTS 
was 26% for men and 
39% for women. 
Nacey et al. [32] New Zealand NR N = 495 men, age ≥ 40 
years 
IPSS Overall = 23% (mild: 
381, moderate: 89 and 
severe 25 men) 













1.5 Factors associated with LUTS 
Published data advocate that increasing age [12-32], geographical differences [33], 
level of education [33-37], working status [35], smoking [13, 33, 37-41], alcohol 
consumption [13, 21] diet [33, 40, 41] and obesity [32] are contributory factors of 
LUTS. High total energy and sodium intake increases the likelihood of LUTS. Total 
fat (saturated or monounsaturated) or carbohydrate intake do not impact LUTS. 
However, increased protein intake decrease the likelihood of LUTS [40]. Maserejian 
et al. reported that greater consumption of dietary lycopene, β-carotene, total 
carotenoid, or vitamin A decreased likelihood of LUTS whereas vitamin C had 
positive association with LUTS [41]. 
 
Apart from afore-mentioned factors, medical diseases and conditions such as 
autoimmune diseases, diabetes, hypertension, renal impairment, persistent cough, 
constipation, chronic obstructive pulmonary disease, chronic heart failure, sleep 
apnea, spinal injuries, spondylitis, and neurological and psychiatric diseases cause 
lower urinary tract dysfunction [42, 43]. In addition, men may suffer LUTS due to 
prostatitis, benign prostatic hyperplasia or prostate cancer whereas females due to 
childbirth or as a consequence of post-menopausal urogenital changes [44]. Moreover, 
surgeries or operations such as simple hysterectomy, radical hysterectomy, ovarian 
and prolapse surgeries can precipitate or exacerbate LUTS [45]. 
 
Several medications can also precipitate or worsen LUTS through effects on bladder 
detrusor muscles and urinary sphincter function [46, 47]. The use of antihypertensive 
medications (diuretics, calcium channel blocker, angiotensin converting enzyme 




anti-Parkinson drugs, anti-dementia drugs, decongestants and antiallergics, 
antihistamines, non-steroidal anti-inflammatory drugs, bronchodilators, 
sympathomimetic, anticholinergics, drugs for acid-related disorders, antiarrhythmics 
(class 1 and 3), cardiac stimulants (excluding cardiac glycosides) and opioids have all 
been implicated to some extent in the onset or aggravation of LUTS [44, 48-66]. 
Effects of several medications that can contribute to urinary symptoms, particularly 


























Alpha agonists Increase smooth muscle tone in urethra 
and prostatic capsule and may precipitate 
obstruction, urinary retention, and related 
Symptoms 
Alpha blockers Decrease smooth muscle tone in the 
urethra and may precipitate stress urinary 
incontinence 
Angiotensin converting enzyme 
inhibitors 
Cause cough that can exacerbate urinary 
incontinence 
Anticholinergics May cause impaired emptying, urinary 
retention, and constipation that can 
contribute to UI. It may also cause 
cognitive impairment and reduce 
effective toileting ability 
Calcium antagonists May cause impaired emptying, urinary 
retention, and constipation that can 
contribute to UI. 
May also cause dependent edema which 
can contribute to nocturnal polyuria 
Cholinesterase inhibitors Increase bladder contractility and may 
precipitate urgency urinary incontinence 
Diuretics Cause diuresis and precipitate urinary 
incontinence 
Lithium Polyuria due to diabetes insipidus 
Opioids May cause urinary retention, 
constipation, confusion, and immobility, 






Histamine 1 receptor antagonists 
May cause confusion and impaired 
mobility and precipitate urinary 
incontinence Anticholinergic effects 
Confusion 
Selective serotonin reuptake inhibitors Increase cholinergic transmission and 
may lead to urinary incontinence 
Miscellaneous 
Gabapentin Can cause edema, which can lead to 
nocturnal polyuria and cause nocturia and 
nocturnal incontinence 
Glitazones 
Nonsteroidal anti-inflammatory drugs 





1.6 Impact of LUTS on patients and society 
LUTS are known to be associated with great emotional burden to people [67] as well 
as high economic burden to the society [68-70]. 
1.6.1 Impact on patients’ quality of life 
Published literature shows that LUTS cause significant reduction in quality of life 
(physical health, psychological health, vitality and social relationships). A cross-
sectional survey of Turkish men aged ≥ 50 (N = 450) reported significantly less mean 
scores in all dimensions (physical functions, physical role, bodily pain, general health 
perceptions, vitality, emotional role, mental health and social functions) of Short-
Form 36 health-related QOL scale among individuals suffering from moderate or 
severe LUTS than those with none-mild urinary symptoms [37]. Similarly, Welch et 
al. [71] reported that increased LUTS severity from the none-mild through to the 
severe LUTS displayed a strong dose-related influence of LUTS severity on all eight 
dimensions of Short-Form 36 health-related QOL scale. Pintarelli et al. [72] used 
World Health Organization-QOL (WHOQOL) scale to assess the QOL among 
individuals (aged ≥ 65) with moderate-severe and none-mild LUTS. They reported 
that individuals having moderate or severe LUTS had significantly worse mean scores 
in all domains of WHOQOL-Bref scale (physical health, psychological health, social 
relationships and environment) than those with no or mild LUTS. Using International 
Prostate Symptom Score-QOL index, Foucade et al. [73] revealed a significant impact 
of LUTS on individuals‘ QOL. Only 10% of their study participants claimed they 







1.6.2 Economical burden 
A study conducted in 6 European nations (Germany, France, Italy, Poland, Spain and 
the UK) to evaluate the medical consumption associated with LUTS suggestive of 
BPH and its treatment expenditures reported that the mean annual treatment costs per 
patient were €858 [69]. Pharmacotherapy was the most significant cost driver, 
accounting for approximately three quarters of total treatment expenditure. 
Surgery/operation and diagnostic testing accounted for 15 and 8% of total costs, 
respectively. Moreover, annual treatment costs for patients with mild, moderate and 
severe obstructive symptoms were €673, €906 and €960, respectively (p < 0.001). For 
patients with mild, moderate and severe irritative symptoms, mean annual treatment 
costs were €623, €865 and €1,043, respectively (p < .001)  Another 
pharmacoeconomic study conducted in Spain reported that mean annual cost of 
diagnostic testing and clinical visits of mild, moderate and severe BPH-related LUTS 
were €124, €207, and €286 per patient, respectively [70]. These findings demonstrate 
the enormous economic burden of LUTS not only on patients and their families but 
also on healthcare system. 
 
1.7 Problem statement 
Around 40% of adults aged 25 years and above suffer from hypertension across the 
globe [74]. Calcium channel blockers (CCBs) are among the most commonly used 
agents for the treatment of hypertension, arrhythmias and angina pectoris [75]. The 
Eighth Joint National Committee (JNC-8) recommended the use of either thiazide-
type diuretics or CCBs or angiotensin converting enzyme inhibitors (ACEIs) or 





CCBs can precipitate or exacerbate voiding, storage and post-voiding urinary 
symptoms due to their natriuretic and diuretic properties [77-84], anticholinergic 
activity (Nifedipine) [85, 86], and inhibition of bladder contraction by blocking L-
type voltage-dependent calcium channels in the detrusor muscles [87-90]. Urinary 
symptoms can lead to decreased quality and quantity of sleep [91], depression [92], 
and a significant reduction in patient‘s QOL [37, 69-71]. 
 
Despite CCB‘s widespread use to treat various cardiovascular diseases worldwide, 
there is limited data concerning the association of these agents with urinary symptoms 
(Table 2.3 in chapter 2). Additionally, due to the advancement in medical research, 
many new medications containing CCBs combinations with other antihypertensive 
agents and lipid lowering agents are available in the drug market. This justified 
further investigation to explore the effect of CCB mono- and combined therapy with 
other antihypertensive agents on LUTS. 
 
1.8 Research objectives 
The objectives of the current study were as follows; 
1. To translate and validate the international prostate symptom score into Urdu 
language. 
2. To evaluate LUTS among CCB mono- and combined therapy users and 
determine the factors associated with moderate-severe and severe LUTS. 
3. To assess the association of LUTS with sleep disturbances and depression 
among CCB-users. 





1.9 Significance of the study 
This study will provide much needed insight on the association of CCB with LUTS 
and reveal the burden of urinary symptoms among CCB-users. In addition, a validated 
Urdu instrument/questionnaire to measure urinary symptoms will be developed in this 
study. It will be a part of scientific literature and therefore assist the future 
investigators regarding the involvement of CCB therapy in the development or 
worsening of LUTS and its impact on patients‘ sleep, depression and health-related 
QOL. 
 
1.10 Conceptual frame work 
Conceptual frame work of Phase-I (psychometric validation study) and Phase-II 
(cross-sectional study) are illustrated in Figure 1.1 and 1.2, respectively. A valid and 
reliable instrument (International prostate symptom score-Urdu) to assess the 
frequency and severity of urinary symptoms among Urdu-speaking population was 
developed in the Phase-I. This validated instrument was used to evaluate the effect of 
CCB mono- and combined therapy with other antihypertensive agents on urinary 































Figure 1.1: Conceptual framework of psychometric validation study (Phase-I) 
 
Abbreviations: AUA-SI = American Urological Association Symptom Index; NIH-
CPSI = National Institute of Health Chronic Prostatitis Symptom Index; ICIQ-
MLUTS = International Consultation on Incontinence Modulation Questionnaire-
Male Lower Urinary Tract Symptoms; ICIQ-FLUTS = International Consultation on 
Incontinence Modulation Questionnaire-Female Lower Urinary Tract Symptoms; 
ICIQ-N = International Consultation on Incontinence Modulation Questionnaire-
Nocturia; ICIQ-OAB = International Consultation on Incontinence Modulation 
Questionnaire-Overactive bladder; IPSS-International Prostate Symptom score  
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Figure 1.2: Conceptual framework of cross-sectional study (Phase-II) 
 
Abbreviations: CCB = calcium channel blockers; CCB = calcium channel blockers; 
CESD = Center for Epidemiologic Studies Short Depression Scale LUTS = lower 
urinary tract symptoms; IPSS-International Prostate Symptom score; JSEQ = Jenkins 
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SYSTEMATIC LITERATURE REVIEW 
2.1 Background 
2.1.1 Calcium channel blockers (CCBs) 
Discovered by Albrecht Fleckenstein in 1960s [93], calcium channel blockers (CCBs) 
were introduced for the first time in medical practice in 1980s. These are commonly 
used agents for the treatment of hypertension, angina pectoris, and supraventricular 
arrhythmias. CCBs are a group of heterogeneous agents having distinct chemical 
structure and pharmacological action [75]. 
 
2.1.2 Clinical Pharmacology of CCBs 
Several classifications of CCBs have been suggested since their introduction into the 
market. The oldest and most acknowledged classification is based upon their chemical 
structures. According to which CCBs are classified into three subclasses namely, 
benzothiazepine derivatives (e.g. diltiazem), phenylalkylamine derivatives (e.g. 
verapamil), and dihydropyridine deriatives (e.g. amlodipine, felodipine, nifedipine, 
nicardipine, lercanididpine, nimodipine, isradipine, nisoldipine etc.) [94].  
 
Another classification system classified CCBs into three categories namely, A, B and 
C. Of these, class A and B block calcium-dependent excitation-contraction coupling 
whereas class C possess less specific, less effective on excitation-contraction coupling 
[95, 96]. After the identification of numerous types and sub-types of calcium channels 




CCBs act on voltage-gated L-type slow Ca2+ channels whereas nonselective on 
voltage-gated L-type, N-type, and P-type Ca2+ channels [97]. Toyo-Oka and Nayler 
proposed that CCBs be categorized into three main groups namely, 1st, 2nd and 3rd 
generation agents [98, 99]. This classification was based on the clinical effects of 
CCBs on receptor binding properties, tissue selectivity, and pharmacokinetics. 
Nifedipine, verapamil and diltiazem were included in the first generation CCBs. 
Second generation CCBs had two subclasses (class IIa and IIb). Class IIa included 
slow/extended release nifedipine, nicardipine, felodine, diltiazem and verapamil 
whereas class IIb included agents with high vascular selectivity (e.g. felodipine, 
israpidine, nicardipine, nimodipine etc.). Third generation class included amlodipine. 
 
Table 2.1: Classification of voltage-gated calcium channels  
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R (residual) High Nural tissue Neurotransmitter 
release 
Cadmium 
T (transient) Low Postsynaptic nerve 










All afore-mentioned agents are vasodilators and their vasodilator potency differs 
according to subclasses, with dihydropyridine derivatives being more potent than the 
benzothiazepine and phenylalkylamine derivatives [94]. Dihydropyridine derivatives 
variably affect heart rate. Acutely, these agents tend to cause reflex tachycardia, 
however long-term investigations reveal similar heart rates prior and during 
dihydropyridine CCBs therapy. Moreover, dihydropyridine derivatives are less likely 
to decrease cardiac output than non-dihydropyridine CCBs. Non-dihydropyridines 
(verapamil and diltiazem) can reduce pulse rate by 10% and increase negative 
inotropic effect [94]. 
 
2.1.3 Prevalence of CCBs use 
An evidenced-based guideline of JNC-8 for the treatment of high blood pressure (BP) 
recommends the selection among four antihypertensive medication classes (CCBs, 
ACEIs, ARBs and thiazide-type diuretics) as preferred Initial pharmacological 
therapy to treat hypertension [76]. Around 30-50% of patients are prescribed CCBs 
for the treatment of hypertension [100-104]. CCBs are the most commonly prescribed 
antihypertensive agents followed by beta-antagonists and ACEIs in Indo-Asian 
nations [100-102]. In Pakistan, CCBs are the most frequently used antihypertensive 








2.1.4 Side effects profile of CCBs  
Side effects of CCBs depend upon the individual CCB within the subclasses, but can 
include nausea, headache, dizziness or light-headedness, constipation, peripheral 
edema, flushing, transient hypotension, bradycardia or heart block, and rash [105-
107]. CCBs are also reported to be associated gastroesophageal reflux disease 
symptoms (e.g. heart burns, indigestion, acid reflux, chest pain, bloating, burning 
throat and bitter taste) by interfering with lower esophageal sphincter [108] and 
polyuria due to natriuresis [77]. 
 
2.1.5 CCBs and bladder function 
Several mechanisms have been suggested to explain CCBs involvement in the 
development of urinary symptoms: (1) natriuresis and diuresis, (2) anticholinergic 
activity, and (3) detrusor muscle relaxation. 
 
2.1.5(a) Natriuretic and diuretic effects 
CCBs have been found to possess natriuretic and diuretic properties in acute studies 
conducted in both experimental animals and humans [77-84]. Zanchetti and Leonati 
suggested that natriuresis and diuresis associated with CCBs might be attributable to 
one or more of the following mechanisms: (1) an alteration in glomerular filtration 
rate and/or renal blood flow, (2) interference with renin secretion, (3) interference in 
aldosterone secretion and/or its action on distal convoluted tubules, (4) interference 
with adrenergic sodium handling and (5) a direct tubular action [82]. However, the 
most likely mechanism is diminished tubular sodium reabsorption [83]. This provides 
reasonable explanation of CCBs-induced storage symptoms. However, it does not 
provide any justification related to CCBs-related voiding symptoms. 
